Fig. 3From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapyKaplan–Meier analyses of 149 patients with stage IIIB-IV NSCLC. a Progression-free survival curves according to SUVmax. b Overall survival curves according to SUVmax. c Progression-free survival curves according to LMR. d Overall survival curves according to LMRBack to article page